• slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • Sponsors’ Testimonials
    “Cordial thanks for the good news and consequently successful conclusion of the study! Again many thanks to the entire pharm-analyt team for the great work! In case of a next PK study, we will gladly come back to you! Best regards“

    Mr. K. N. – Specialized Medium Pharma, Germany
  • Sponsors’ Testimonials
    “The only supplier fixed for the upcoming study is pharm-analyt, - you saved us in the last study!”

    Mrs. Y. R. – Medium Pharma, North America
  • Sponsors’ Testimonials
    “I must say that I do not remember a nicer and personal atmosphere for a science meeting than what we experienced in Vienna. Thank you so much! With the warmest regards”

    Mr. N. B., Biotech, Scandinavia
  • Sponsors’ Testimonials
    “Chosing pharm-analyt has paid back manifold! I am so much looking forward to the next project with you!“

    Mrs. C. A. – Medium Pharma, Austria
  • Sponsors’ Testimonials
    “Let me take the opportunity to thank you for the comprehensive support and the highly professional execution by you and the team! I would be delighted to collaborate again in the future”

    Mr. M. J. – Biotech, Austria
  • Sponsors’ Testimonials
    “Where else would you go for tissue analysis other than pharm-analyt?!”

    Mr. B. B., - Big Pharma, Germany
  • Sponsors’ Testimonials
    “Thanks a lot for providing this information - it looks like another good piece of work from you!”

    Mr. H. S. – Biotech, Scandinavia
  • Sponsors’ Testimonials
    “pharm-analyt provided the perfect solution for our complicated challenge! Experimental setup, validation, tests and reporting were done in a fast and professional way!

    We were extremely satisfied and will definitively come back!”

    R. B. - Biotech, Austria
  • Sponsors’ Testimonials
    “pharm-analyt has always given us a highly valuable answer to our bioanalytical needs in a timely and proactive manner!”

    E. C. - Tox Consultant, Spain

About Us: Curious by Nature

Founded in 1986, in Baden/Vienna (Austria), pharm-analyt was providing analytical services long before HPLC-MS was widespread. Since the beginning, curiosity has been the driving force at pharm-analyt to discover the interrelatedness of the subject. This understanding of the inherent causes & effects of biochemistry is what differentiates us.

The majority of our work today is based on mass spec technology. pharm-analyt is privately owned and therefore fully independent.


Nothing is impossible


Analytical Acumen – Backed by State of the Art Technology.

When asked about the secret of our success, besides curiosity, two more things come to mind:

- Vast experience accumulated over the last three decades
- Visionary investment in state-of-the-art instrumentation

Management

Team - Prof. Hermann Mascher

 

 

Prof. Hermann Mascher

Founder and Bioanalytical Consultant


Hermann Mascher is the founder and former CEO of pharm-analyt. A chemist and analyst, he has made a name for himself in the course of the past 45 years in the fields of bioanalytics, metabolism and pharmacokinetics.

He will continue his employment at pharm-analyt as Bioanalytical Consultant with a focus on biomarkers and new approaches in assay development.

Most of his scientific papers have been published in peer-reviewed journals.

First awarded a “Who’s Who in the World” listing over 20 years ago, he is the recipient of a number of innovation and science prizes.

Hand-in-hand with the company’s specialist scientific focus, the Management Team at pharm-analyt is also conscious of an ethical obligation in the world at large, derived from a deeply held faith in Jesus Christ. This is why it supports several programmes aimed at improving people’s living conditions in both material, social and psychological terms – especially, although not only, for children and young people.

pharm-analyt believes that today’s world offers no shortage of opportunities for people to get involved in improving the lives of others, both as citizens and as Christians.

 

Prof. Hermann Mascher
Founder/Bioanalytical Consultant

Team - Daniel Mascher

Dr. Daniel Mascher

Chief Operating Officer (COO)

 

Together with the study directors, he is the point of contact for sponsors during the implementation of their studies.
Daniel Mascher is a physicist, whose doctoral thesis was in the field of bioanalytics, on HPLC mass spectrometry of trace-level organic molecules.

This area of knowledge – greatly extended at pharm-analyt over many years as GLP/GMP/GCP-study director – is one which he brings to bear very effectively as the COO, facilitating an efficient mode of working among our in-house study directors. He heads a youthful team of analysts and covers both test facility management (GLP) and control laboratory management (GMP).

For GMP studies 2 Qualified Persons (QP), Dr. Klaus Kubesch and Mag. Christian Kikuta, support him.

 

 

 

 

Dr. Daniel Mascher
Chief Operating Officer (COO)

Team - Klaus Mascher

 

 

MMag. Klaus Mascher

Chief Executive Officer (CEO)


With a business administration background and after two years in documentation at pharm-analyt Klaus took over as CEO in 2017. In 2020 he experienced his most challenging year as a CEO building on his logistics major in order to implement new rules and procedures to get through the pandemic.

 

MMag. Klaus Mascher
Chief Executive Officer (CEO) and Head of Marketing

Head of Departments

Team - Elisabeth Feik

 

 

Dipl.-Ing. Elisabeth Feik

Head of Documentation and COO by proxy


Elisabeth joined pharm-analyt in 2015 and became a valuable member of the team. Her focus on quality on many levels has led to more solid and understandable documents that go out to clients. With her social competence also the team spirit has increased.

 

Dipl.-Ing. Elisabeth Feik
Head of Documentation and
COO by proxy

Philipp Schlögel
Head of IT

For more info on a person please click on the image


GMP Regulatory Team

Dr. Klaus Kubesch
Qualified Person,
joined pharm-anayt in 2003

Dr. Timo G. Kretzschmar
Head of QA

Dr. Kristof Meelich
Qualified Person




Our Team

Due to low staff fluctuation over the last 30 years we are proud to have a team with an invaluable wealth of experience and skills. We feel privileged to be able to do what we love: bioanalysis and everything related.

This is reflected in the high level of ownership for the entire process from start to finish.



Company History

  • 1986
  • 1990s
  • 2000s
  • 2010-2014
  • 2015-2019
  • 2020-2024

  • Founding of "pharm-analyt Labor GmbH"

  • 1992
    First GLP certification

    1995
    Introduction of mass spectrometry at pharm-analyt

    1998
    pharm-analyt acquires an API 3000 tandem mass spectrometer

    1999
    More than 50 % of the annual turnover achieved from mass spectrometry

  • 2001
    pharm-analyt is among the first companies in Europe to operate an API 4000 mass spectrometer

    2002
    Fundamental research on acylcarnitines and Sudden Infant Death Syndrome (SIDS)

    2003
    Development of an LC/MS method with a lower limit of quantitation of less than 1 pg/mL (400 fg/mL formoterol in human serum)
    Implementation of an Electronic Archiving System

    2004
    Intensified focus on protein binding of drugs

    2005
    Antioxidative capacity testing with different methods

    2006
    An API 5000 mass spectrometer is added to pharm-analyt’s instrument pool

    2008
    Purchase of LTQ Orbitrap XL high resolution / high mass accuracy mass spectrometer

     

  • 2010
    Strong focus on biomarker identification for rare lysomal diseases

    2011
    Two European Patents for rare diseases (Gaucher, NPC)

    2012
    Publication of book "HPLC Methods for Clinical Pharmaceutical Analysis - A User´s Guide"

    2013
    Purchase of the MS-system QTRAP 6500® with SelexION system from AB Sciex
    New Website and updated corporate design

    2014
    We added a second multiplexing unit to one of our MS instruments allowing for 2 HPLC streams on one MS detector

  • 2015
    New HPLC systems and new ELSD detector / Integration in GMP environment
    Additional mass-spec-system QTRAP 6500® from AB Sciex

    2016
    3 biomarker patents sold
    Implementation of PERSEUS software for structure elucidation
    pharm-analyt celebrates 30th anniversary!

    2017
    New CEO, second Qualified Person (GMP), ready for another 30 years!

    2018
    Strong focus on new biomarkers for Kabuki-Syndrom, Sepsis and MS (Multiple Sclerosis).

    2019
    Purchase of the MS system XEVO TQ-XS with UniSpray source and UPLC from Waters

  • 2020
    The organizational year:
    From an organizational perspective the most challenging year of the company, almost half a year of split team arrangement and new infrastructure in order to control the pandemic on site. In fall fresh air ventilation systems for both lab and office floor and air purifiers for all offices were installed.

    2021
    New biomarker:
    After years of research BM1, a biomarker predicting a sepsis condition, was published under the International Publication Number WO 2021/239413 A1 on 2 December 2021

    2022
    Regulatory year:
    Certificate of GLP and GMP compliance signed in Q1/2022 by the Austrian Authority BASG, both valid until Q4/2024

    2023
    QP year:
    Another qualified person at pharm-analyt replacing a retired predecessor

    2024
    New CAD:
    Elongated Charged aerosol detector non-GxP feasibility compared with already long GMP-established electronic light scattering detector. Both have their value.

 

 


 

Our Clients